NR4A3 and chronic myelogenous leukemia, BCR-ABL1 positive: With disease progression to accelerated phase (CML-AP) and then to acute blastic change (CML-ABC) stages, the NR4A3 expression levels were gradually decreased, consistent with the expectation for a class II aberration in leukemic cells with progressive differentiation impairment (Fig. 4A).